ETX-155 is a small molecule commercialized by Eliem Therapeutics, with a leading Phase I program in Partial Seizure. According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of ETX-155’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ETX-155 is expected to reach an annual total of $53 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ETX-155 is under development for the treatment of major depressive disorder (MDD), perimenopausal depression and focal onset seizures (FOS). The drug candidate is administered through oral route. It is a next-generation, neuroactive steroid new chemical entity (NCE) that acts by targeting GABA A type receptor.
Eliem Therapeutics Overview
Eliem Therapeutics is a biotechnology company that develops and markets novel therapies for the treatment of chronic pain, psychiatry, epilepsy and other peripheral and central nervous system disorders. The company is headquartered in Redmond, Washington, the US.
The operating loss of the company was US$35.7 million in FY2021, compared to an operating loss of US$20.9 million in FY2020. The net loss of the company was US$47.5 million in FY2021, compared to a net loss of US$20.7 million in FY2020.
For a complete picture of ETX-155’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.